Ana Rivas Mejia, MD
Endocrinology, Diabetes & Metabolism · Springfield, MONPI 1275898017
Payments from drug & device makers
Across 177 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$686
- Dexcom, Inc.$488
- Amgen$346
- Lilly USA, LLC$337
- Novo Nordisk$247
- plus $1K from 21 others
What the payments were for
- Travel & lodging$88118%
- Food & beverage$3,93281%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 15 | $1,745 |
| Abbott | 39 | $686 |
| Dexcom, Inc. | 32 | $488 |
| Amgen | 16 | $346 |
| Lilly USA, LLC | 18 | $337 |
| Novo Nordisk | 13 | $247 |
| Recordati_rare_diseases_inc. | 5 | $179 |
| Sanofi-aventis U.S. LLC | 7 | $145 |
| Amarin Pharma, Inc. | 1 | $98 |
| Chiesi USA, Inc. | 3 | $63 |
| Boehringer Ingelheim | 4 | $61 |
| AstraZeneca | 1 | $60 |
| Radius Health, Inc. | 2 | $55 |
| Insulet Corporation | 2 | $44 |
| Novartis | 3 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Pfizer | 2 | $33 |
| Bayer | 2 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Antares Pharma, Inc. | 2 | $28 |
| Intuity Medical Inc | 1 | $24 |
| Corcept Therapeutics | 1 | $24 |
| Alvogen Inc | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| AbbVie | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,284
- TEPEZZA$123
- DEXCOM CGM$100
How this compares
$4,883 in reported general payments places this provider in the 65th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 148 | $206,331 |
| JardianceEmpagliflozin | 151 | $147,702 |
| TrulicityDulaglutide | 77 | $122,071 |
| Tresiba Flextouch U-200Insulin Degludec | 70 | $78,054 |
| Teriparatide | 18 | $49,141 |
| JanuviaSitagliptin Phosphate | 38 | $41,496 |
| MounjaroTirzepatide | 31 | $40,565 |
| FarxigaDapagliflozin Propanediol | 41 | $39,021 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $28,720 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $25,230 |
| RybelsusSemaglutide | 11 | $20,818 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $19,781 |
| TradjentaLinagliptin | 28 | $18,593 |
| Novolog FlexpenInsulin Aspart | 61 | $18,151 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $17,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $247 | $230,842173 claims |
| Boehringer IngelheimJardiance, Tradjenta | $61 | $166,295179 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30, Insulin Lispro | $337 | $165,418132 claims |
| Alvogen IncTeriparatide | $23 | $49,14118 claims |
| AstraZenecaFarxiga | $60 | $39,02141 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $145 | $21,24830 claims |
| AbbVieSynthroid | $16 | $4,55951 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Springfield
- Ralph DudaSpringfield$3M
- Gregory LedgerSpringfield$690K
- Jonben SvobodaSpringfield$142K
- James BonucchiSpringfield$128K
- Thomas NickolasSaint Louis$945K
- Anne GoldbergSaint Louis$830K
- Janet McGillSaint Louis$828K
- Christopher CaseJefferson City$692K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.